SER Serina Therapeutics Inc.

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: SER

Price (delayed)

$9.191

Market cap

$22.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$13.72

Enterprise value

$26.95M

agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic ...

Highlights
The equity has surged by 132% year-on-year and by 120% since the previous quarter
Serina Therapeutics's gross profit has surged by 89% QoQ
The company's debt has surged by 97% QoQ but it has shrunk by 76% YoY
The quick ratio has dropped by 50% since the previous quarter but it rose by 14% year-on-year
The net income has declined by 41% year-on-year and by 5% since the previous quarter
The company's EPS fell by 41% YoY and by 3.8% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.agexinc.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of SER
Market
Shares outstanding
2.5M
Market cap
$22.98M
Enterprise value
$26.95M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.81
Price to sales (P/S)
69.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
189.81
Earnings
Revenue
$142,000
EBIT
-$9.9M
EBITDA
-$9.77M
Free cash flow
-$7.8M
Per share
EPS
-$13.72
Free cash flow per share
-$7.23
Book value per share
$5.07
Revenue per share
$0.13
TBVPS
$10.53
Balance sheet
Total assets
$11.97M
Total liabilities
$6.61M
Debt
$4.37M
Equity
$5.47M
Working capital
-$5.16M
Liquidity
Debt to equity
0.8
Current ratio
0.13
Quick ratio
0.08
Net debt/EBITDA
-0.41
Margins
EBITDA margin
-6,881.7%
Gross margin
71.8%
Net margin
-10,424.6%
Operating margin
-6,954.9%
Efficiency
Return on assets
-120.9%
Return on equity
N/A
Return on invested capital
-67.9%
Return on capital employed
-163.7%
Return on sales
-6,973.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SER stock price

How has the Serina Therapeutics stock price performed over time
Intraday
-8.09%
1 week
-15.91%
1 month
-27.17%
1 year
1,314%
YTD
2,287.27%
QTD
-38.2%

Financial performance

How have Serina Therapeutics's revenue and profit performed over time
Revenue
$142,000
Gross profit
$102,000
Operating income
-$9.88M
Net income
-$14.8M
Gross margin
71.8%
Net margin
-10,424.6%
Serina Therapeutics's gross profit has surged by 89% QoQ
The company's net margin has surged by 66% YoY and by 30% QoQ
The company's operating margin has surged by 66% YoY and by 20% QoQ
The revenue has surged by 51% since the previous quarter

Growth

What is Serina Therapeutics's growth rate over time

Valuation

What is Serina Therapeutics stock price valuation
P/E
N/A
P/B
1.81
P/S
69.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
189.81
The company's EPS fell by 41% YoY and by 3.8% QoQ
The equity has surged by 132% year-on-year and by 120% since the previous quarter
The price to sales (P/S) is 86% lower than the last 4 quarters average of 491.0 and 73% lower than the 5-year quarterly average of 256.7
The revenue has surged by 51% since the previous quarter

Efficiency

How efficient is Serina Therapeutics business performance
Serina Therapeutics's ROA has soared by 70% YoY and by 13% from the previous quarter
The company's return on sales has surged by 67% YoY and by 20% QoQ
The ROIC rose by 40% YoY but it fell by 23% QoQ

Dividends

What is SER's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SER.

Financial health

How did Serina Therapeutics financials performed over time
Serina Therapeutics's total assets is 81% higher than its total liabilities
The company's total liabilities has surged by 70% QoQ but it has shrunk by 68% YoY
The company's current ratio has shrunk by 64% QoQ and by 46% YoY
The company's debt is 20% lower than its equity
The debt to equity has surged by 176% year-on-year
The equity has surged by 132% year-on-year and by 120% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.